Does perioperative chemotherapy improve outcomes in PDAC? Evidence is not yet conclusive
Trials provide insights into perioperative and adjuvant chemotherapy for resectable pancreatic cancer
Trials provide insights into perioperative and adjuvant chemotherapy for resectable pancreatic cancer
Addition of abiraterone acetate plus prednisone shows clear survival improvements in castration-sensitive prostate cancer
Good response rate and disease control with adagrasib and sotorasib in combination therapy shown in early-stage trials
Results from the SAKK 01/10 trial demonstrate favourable progression-free survival and low toxicity with single-dose carboplatin and involved-node radiotherapy
Final overall survival results from the KEYNOTE-355 study confirm immune checkpoint inhibitors as the first-line treatment of choice in women with metastatic or relapsing disease
Seemingly disappointing survival findings in the final results from the PEARL study are balanced by better quality of life with combination therapy
Significant progression-free survival benefits in pre-treated HER2-positive metastatic disease reported in the DESTINY-BREAST03 and SYD985.002/TULIP trials
Multi-omics approaches incorporating cell-free DNA and circulating tumour DNA show potential in early cancer detection and could help personalise treatment by tumour characteristics
Early-phase studies, COSMIC-021 and CheckMate 9KD, show promising results in men with prostate cancer, but patient selection is key
This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.
For more detailed information on the cookies we use, please check our Privacy Policy.
Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.